Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.35 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4774585 | 0.79 | — | — | |
| SCHEMBL27702118 | 0.75 | DPP4 (0.33) | — | |
| SCHEMBL23724953 | 0.73 | MTOR (0.32) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL18400776 | 0.73 | — | — | |
| SCHEMBL14107996 | 0.73 | CHRNB2 (0.31) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL27738862 | 0.73 | CHRNB2 (0.33) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL27722583 | 0.72 | POLB (0.35) | — | |
| SCHEMBL19010439 | 0.71 | KMT2A (0.34) | CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL25939248 | 0.71 | CHRNB2 (0.33) | CHRNB2CHRNA4CHRNB4CHRNA3FFAR2 | |
| SCHEMBL11996286 | 0.70 | TP53 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580802-B2 | Pyrrolo[2,3-D]pyrimidines as inhibitors of Janus kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-11-12 | — | — | US | disclosed |
| US-20070207995-A1 | Deazapurines useful as inhibitors of Janus kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207995-A1 | Deazapurines useful as inhibitors of Janus kinases | JAK1, JAK3, JAK2 | CHRNB2 4878/4885CHRNA4 4866/4885CHRNB4 4880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.